Results 61 to 70 of about 5,617 (307)

Plaque‐Hepatic Targeting Nanotherapy Disrupts the PCSK9‐LOX‐1 Axis to Suppress oxLDL in Atherosclerosis

Advanced Science, EarlyView.
Self‑amplifying PCSK9–LOX‑1 feedback axis drives atherosclerotic progression by promoting oxLDL generation and endothelial uptake. A dual‑targeting nanoplatform (siPCSK9@PEAL NPs‑aL) is constructed to simultaneously silence hepatic PCSK9 for lipid lowering and block plaque LOX‑1 for anti‑inflammation.
Yi Duan, Yijie Qiu, Yan Zhu, Quan Wang, Jiangtao Lin, Yourong Duan, Qi Wang, Yi Dong   +7 more
wiley   +1 more source

Effect of flaxseed powder on cardiovascular risk factor in dyslipidemic and hypertensive patients

International Journal of Preventive Medicine, 2019
Background: Hyperlipidemia and hypertension are the most important causes of ischemic heart disease. There is evidence that flaxseed powder can improve lipid profile and blood pressure. In this study, we want to investigate the effects of flaxseed powder
Naemeh Haghighatsiar, Gholamreza Askari, Sahar Saraf-Bank, Avat Feizi, Hasan Keshmiri   +4 more
doaj   +1 more source

Treatment of Hyperlipidemia.

Internal Medicine, 2000
In the treatment of hyperlipidemia, when to begin and end therapy is important. In recent years, potent anti-hyperlipidemia drugs have been widely used, and the results of many intervention trials have shown that combinations of diet, exercise and drug therapies are effective for the primary and secondary prevention of coronary heart disease.
openaire   +3 more sources

APPLICABILITY OF PHYTOSTEROLS ON HYPERERCOLESTEROLEMIA IN HEALTHY DOGS

, 2018
Phytosterols are extracted from some vegetables and cereals with high lipid content and are used as lipid-lowering agents in the prevention of obesity and cardiovascular diseases in people.
Crivellenti, Sofia BorinCrivellenti Borin, Mendes, Pamela Almerinda Mendes Almerinda, Lima, Fernando Reis Lima Reis, Oliveira, Frederico Rocha, Bergamo, Isabelle Cristina Bergamo Cristina, Costa, Paula Barbosa Costa Barbosa, Silva, Maria Fernanda Silva Fernanda, Crivellenti, Leandro Zucolloto   +7 more
core   +1 more source

Image1_Developing a Core Outcome Set for Clinical Trials of Chinese Medicine for Hyperlipidemia.JPEG

, 2022
Background: Chinese medicine (CM) is widely used for treating hyperlipidemias, especially in China. However, the heterogeneity of outcomes measured and reported across trials exacerbates the obstacles of evidence synthesis and effectiveness comparison ...
Zehuai Wen (2504662), Mingjun Lin (12486223), Xiankun Chen (534228), Ruxue Han (12486220), Geng Li (312002)   +4 more
core   +1 more source

Phase Separation of TRIM21 Modulates PTPN14 Stability to Drive Flow‐Dependent Endothelial Activation and Atherogenesis

Advanced Science, EarlyView.
Disturbed flow promotes the formation of TRIM21‐rich biomolecular droplets, which concentrate TRIM21 and PTPN14 and facilitate their SPRY‐FERM interaction (illustrated by the TRIM21 D355‐PTPN14 R132 salt bridge). This condensate‐driven proximity enables TRIM21 to catalyze K48‐linked polyubiquitination of PTPN14 at lysine 956, leading to proteasome ...
Xue He, Qiannan Ma, Xue Wang, Jiaxu Mang, Chufeng Li, Bingjun Wu, Liu Yao, Yequn Chen, Qiankun Bao, Yi Zhu, Jinlong He   +10 more
wiley   +1 more source

Antihyperlipidemic Agents Cause a Decrease in von Willebrand Factor Levels in Pediatric Patients with Familial Hyperlipidemia

, 2010
Familial hyperlipidemia is a group of genetic disorders with a predisposition to atherosclerosis. Hyperlipidemia causes increased atherosclerotic events through increased endothelial damage.
Şule Ünal, Güneş, B, Fatma Gümrük, Bülent Güneş, Yalçin, SIDDIKA SONGÜL, Turgay Coşkun, Gümrük, FATMA, S. Songül Yalçin, Unal, ŞULE, Coşkun, T   +9 more
core   +1 more source

Table1_Developing a Core Outcome Set for Clinical Trials of Chinese Medicine for Hyperlipidemia.DOCX

, 2022
Background: Chinese medicine (CM) is widely used for treating hyperlipidemias, especially in China. However, the heterogeneity of outcomes measured and reported across trials exacerbates the obstacles of evidence synthesis and effectiveness comparison ...
Zehuai Wen (2504662), Mingjun Lin (12486223), Xiankun Chen (534228), Ruxue Han (12486220), Geng Li (312002)   +4 more
core   +1 more source

KLF5 Downregulation Links Impaired BNIP3‐Mediated Mitophagy to Inflammatory Valve Remodeling in Calcific Aortic Valve Disease

Advanced Science, EarlyView.
In human CAVD, KLF5 is reduced in VIC‐rich regions and remodeling/stress‐associated VIC states. In VICs, KLF5 sustains BNIP3 promoter activity and BNIP3‐mediated mitophagy, thereby limiting cytosolic mtDNA accumulation. KLF5 loss weakens mitochondrial quality control and enhances mtDNA‐sensitive STING/NF‐κB/NLRP3 inflammatory signaling under osteogenic
Jin‐Hui Bian, Jia‐Xi Gu, Zhang Yue, Chun‐Ze Yuan, Hai‐Bin Ji, Ao Li, Yu Zhong, Xiu‐Fan Xu, Yu‐Qiu He, Ye‐Fan Jiang, Hong‐Shan Chen, Xiang Chen, Meng‐Lin Chao, Yong‐Feng Shao   +13 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source